Schizophrenia Drugs Market Report 2026

Schizophrenia Drugs Market Overview

• Schizophrenia Drugs market size has reached to $8.41 billion in 2025 • Expected to grow to $11.24 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Schizophrenia Cases Drive Growth In The Market    • Market Trend: FDA Approval Of Groundbreaking Oral Medication For Schizophrenia Marks A New Treatment Approach • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Schizophrenia Drugs Market?

Schizophrenia drugs are medications designed to manage the symptoms of schizophrenia, a chronic mental disorder affecting thoughts, perceptions, emotions, and social interactions. By targeting chemical imbalances in the brain, particularly dopamine and serotonin, these drugs help reduce psychosis, stabilize mood, and improve cognitive function, enabling better daily functioning and independence. The main therapeutic classes of schizophrenia drugs are second generation, third generation, and others. Second-generation antipsychotics, or "atypical" antipsychotics, treat schizophrenia by targeting dopamine and serotonin receptors, offering symptom relief with a lower risk of movement disorders compared to first-generation drugs. It is used for several treatments, such as oral and injectable, and it is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

What Is The Schizophrenia Drugs Market Growth Forecast?

The schizophrenia drugs market size is expected to see strong growth in the next few years. It will grow to $11.24 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to rising mental health burden, growth in injectable therapies, increasing access to psychiatric care, digital mental health integration, expanding healthcare funding. Major trends in the forecast period include rising use of second and third generation antipsychotics, increasing adoption of long-acting injectable therapies, growing focus on long-term disease management, expansion of community-based mental healthcare, increased emphasis on treatment adherence.

Global Schizophrenia Drugs Market Segmentation

1) By Therapeutic Class: Second Generation, Third Generation, Other Therapeutic Classes 2) By Treatment: Oral, Injectable 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels Subsegments: 1) By Second Generation: Risperidone, Olanzapine, Quetiapine, Aripiprazole, Paliperidone, Ziprasidone, Others 2) By Third Generation: Brexpiprazole, Cariprazine, Others 3) By Other Therapeutic Classes: First-Generation Antipsychotics, Combination Therapies, Others

What Is The Driver Of The Schizophrenia Drugs Market?

Rising cases of schizophrenia are expected to propel the growth of the schizophrenia drugs market going forward. Schizophrenia is a long-term mental illness marked by impaired thoughts, perceptions, emotions, and behavior, commonly resulting in hallucinations and delusions. The rise in schizophrenia cases is attributed to factors such as genetic predisposition, environmental stressors, substance abuse, and disruptions in brain chemistry. Schizophrenia drugs are utilized to mitigate the cases of schizophrenia through effective symptom management, reducing the impact of the disorder on patients' daily lives and improving overall treatment outcomes. For instance, in February 2024, according to the National Library of Medicine, a US-based biomedical library, the prevalence of schizophrenia and related psychotic disorders ranged from 0.25% to 0.64% of the US population. Furthermore, in January 2024, according to the British Columbia Schizophrenia Society, a Canada-based nonprofit organization, schizophrenia is a major cause of hospitalization for mental illnesses, representing 19.9% of general hospital admissions and 30.9% of stays in psychiatric hospitals. Therefore, rising cases of schizophrenia will drive the growth of the schizophrenia drugs industry.

Key Players In The Global Schizophrenia Drugs Market

Major companies operating in the schizophrenia drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co., Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., Sun Pharmaceutical Industries Ltd., AbbVie Inc., H. Lundbeck A/S, Cipla Ltd., Lupin Limited, Alkermes plc, Vanda Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Mylan NV, Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Holdings Inc., Lifegenix, Flagship Biotech International Pvt. Ltd.

Global Schizophrenia Drugs Market Trends and Insights

Major companies operating in the schizophrenia drugs market are focused on developing advanced products, such as schizophrenia oral medication, to streamline and enhance patient care and treatment outcomes. Oral medications for schizophrenia are drugs taken by mouth to treat the disorder's symptoms, often consisting of antipsychotics that aid in stabilizing mood, thoughts, and perceptions. For instance, in September 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approved Cobenfy, a groundbreaking oral medication designed to treat schizophrenia in adults. This innovative drug combines xanomeline and trospium chloride, marking a significant departure from traditional antipsychotics by targeting cholinergic receptors instead of dopamine receptors. This novel approach has the potential to provide relief from symptoms such as delusions and disorganized thinking while reducing the common side effects associated with older antipsychotic medications, positioning Cobenfy as a promising alternative in the schizophrenia treatment landscape.

What Are Latest Mergers And Acquisitions In The Schizophrenia Drugs Market?

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical industry company, acquired Karuna Therapeutics for $14 billion. The acquisition is expected to bolster Bristol Myers Squibb's neuroscience portfolio by incorporating KarXT, a novel antipsychotic, and broadening its pipeline with potential therapies for schizophrenia, Alzheimer's disease, and other mental health conditions. Karuna Therapeutics is a US-based biopharmaceutical company that manufactures schizophrenia drugs.

Regional Insights

North America was the largest region in the schizophrenia drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Schizophrenia Drugs Market?

The schizophrenia drugs market consists of sales of transdermal patches, liquid formulations, and adjunctive therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Schizophrenia Drugs Market Report 2026?

The schizophrenia drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the schizophrenia drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.